Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study
BackgroundRetinitis pigmentosa is an incurable, degenerative retinal condition causing progressive sight loss, significantly affecting patients’ quality of life. The Argus II Retinal Prosthesis is a surgically implanted medical device that delivers electrical stimulation to the retina. It is intende...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2021-01-01
|
| Series: | JMIR Research Protocols |
| Online Access: | http://www.researchprotocols.org/2021/1/e17436/ |
| _version_ | 1818877245757849600 |
|---|---|
| author | White, Judith Knight, Laura da Cruz, Lyndon Stanga, Paulo E Patrick, Hannah Powell, Helen Berry, Lee Withers, Kathleen Carolan-Rees, Grace Jackson, Timothy L |
| author_facet | White, Judith Knight, Laura da Cruz, Lyndon Stanga, Paulo E Patrick, Hannah Powell, Helen Berry, Lee Withers, Kathleen Carolan-Rees, Grace Jackson, Timothy L |
| author_sort | White, Judith |
| collection | DOAJ |
| description | BackgroundRetinitis pigmentosa is an incurable, degenerative retinal condition causing progressive sight loss, significantly affecting patients’ quality of life. The Argus II Retinal Prosthesis is a surgically implanted medical device that delivers electrical stimulation to the retina. It is intended to produce a form of artificial vision for blind people with severe-to-profound retinitis pigmentosa by stimulating the remaining viable retinal cells to induce visual perception. This study has been initiated by National Health Service England’s Commissioning through Evaluation program and funded through the National Institute of Health Research of the United Kingdom.
ObjectiveThe aim of this study was to assess the effect of the Argus II device on patient’s daily activities and quality of life.
MethodsThis protocol is a prospective, single-arm, open-label, mixed methods study on 10 consecutive participants receiving the Argus II device. The patient representatives played an integral role in the design of this study. Eligibility criteria include ultra-low vision in both eyes as a result of end-stage retinitis pigmentosa and a willingness and capacity to complete the postimplantation rehabilitation program. Participants will be interviewed by independent researchers at baseline and 12 months later by using a semistructured, in-depth approach, alongside validated questionnaires (Impact of Vision Impairment-Very Low Vision, 5-level EuroQoL-5 dimensions scale, EuroQoL-visual analog scale, and Hospital Anxiety and Depression Scale) and a bespoke device-related questionnaire, which includes questions about users’ experiences with the procedure, the device, and rehabilitation. The effect of the device on patients’ functional vision and activities of daily living will be assessed by vision rehabilitation specialists using a set of tests measured on an ordinal scale (eg, ability to locate objects and avoid obstacles). Clinical outcomes include full-field stimulus light threshold, square localization, direction of motion, grating visual acuity, Landolt-C, procedural success, and adverse events. Qualitative and quantitative outcomes will be linked in a single database to enable individual participant measures to be considered in toto, comparing baseline to the final review.
ResultsThis study was approved by the local ethics committee on April 24, 2019 (London-Camberwell St. Giles Research Ethics Committee, reference 19/LO/0429). It has also been approved by the Health Research Authority and Health and Care Research Wales. At the time of protocol writing, Argus II was available for use in the United Kingdom; however, the manufacturer recently withdrew the Argus II device from sale in the United Kingdom. Therefore, the study is not going ahead at this time.
ConclusionsThe mixed methods approach provides a rich and in-depth assessment of the effect of the device on participants’ quality of life. Despite the work not going ahead, the publication of this publicly funded protocol is important for researchers planning similar work.
International Registered Report Identifier (IRRID)PRR1-10.2196/17436 |
| first_indexed | 2024-12-19T13:55:13Z |
| format | Article |
| id | doaj.art-e9674b970c064db3be4b3e977199d2d7 |
| institution | Directory Open Access Journal |
| issn | 1929-0748 |
| language | English |
| last_indexed | 2024-12-19T13:55:13Z |
| publishDate | 2021-01-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Research Protocols |
| spelling | doaj.art-e9674b970c064db3be4b3e977199d2d72022-12-21T20:18:37ZengJMIR PublicationsJMIR Research Protocols1929-07482021-01-01101e1743610.2196/17436Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods StudyWhite, JudithKnight, Laurada Cruz, LyndonStanga, Paulo EPatrick, HannahPowell, HelenBerry, LeeWithers, KathleenCarolan-Rees, GraceJackson, Timothy LBackgroundRetinitis pigmentosa is an incurable, degenerative retinal condition causing progressive sight loss, significantly affecting patients’ quality of life. The Argus II Retinal Prosthesis is a surgically implanted medical device that delivers electrical stimulation to the retina. It is intended to produce a form of artificial vision for blind people with severe-to-profound retinitis pigmentosa by stimulating the remaining viable retinal cells to induce visual perception. This study has been initiated by National Health Service England’s Commissioning through Evaluation program and funded through the National Institute of Health Research of the United Kingdom. ObjectiveThe aim of this study was to assess the effect of the Argus II device on patient’s daily activities and quality of life. MethodsThis protocol is a prospective, single-arm, open-label, mixed methods study on 10 consecutive participants receiving the Argus II device. The patient representatives played an integral role in the design of this study. Eligibility criteria include ultra-low vision in both eyes as a result of end-stage retinitis pigmentosa and a willingness and capacity to complete the postimplantation rehabilitation program. Participants will be interviewed by independent researchers at baseline and 12 months later by using a semistructured, in-depth approach, alongside validated questionnaires (Impact of Vision Impairment-Very Low Vision, 5-level EuroQoL-5 dimensions scale, EuroQoL-visual analog scale, and Hospital Anxiety and Depression Scale) and a bespoke device-related questionnaire, which includes questions about users’ experiences with the procedure, the device, and rehabilitation. The effect of the device on patients’ functional vision and activities of daily living will be assessed by vision rehabilitation specialists using a set of tests measured on an ordinal scale (eg, ability to locate objects and avoid obstacles). Clinical outcomes include full-field stimulus light threshold, square localization, direction of motion, grating visual acuity, Landolt-C, procedural success, and adverse events. Qualitative and quantitative outcomes will be linked in a single database to enable individual participant measures to be considered in toto, comparing baseline to the final review. ResultsThis study was approved by the local ethics committee on April 24, 2019 (London-Camberwell St. Giles Research Ethics Committee, reference 19/LO/0429). It has also been approved by the Health Research Authority and Health and Care Research Wales. At the time of protocol writing, Argus II was available for use in the United Kingdom; however, the manufacturer recently withdrew the Argus II device from sale in the United Kingdom. Therefore, the study is not going ahead at this time. ConclusionsThe mixed methods approach provides a rich and in-depth assessment of the effect of the device on participants’ quality of life. Despite the work not going ahead, the publication of this publicly funded protocol is important for researchers planning similar work. International Registered Report Identifier (IRRID)PRR1-10.2196/17436http://www.researchprotocols.org/2021/1/e17436/ |
| spellingShingle | White, Judith Knight, Laura da Cruz, Lyndon Stanga, Paulo E Patrick, Hannah Powell, Helen Berry, Lee Withers, Kathleen Carolan-Rees, Grace Jackson, Timothy L Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study JMIR Research Protocols |
| title | Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study |
| title_full | Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study |
| title_fullStr | Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study |
| title_full_unstemmed | Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study |
| title_short | Effects of the Argus II Retinal Prosthesis System on the Quality of Life of Patients With Ultra-Low Vision Due to Retinitis Pigmentosa: Protocol for a Single-Arm, Mixed Methods Study |
| title_sort | effects of the argus ii retinal prosthesis system on the quality of life of patients with ultra low vision due to retinitis pigmentosa protocol for a single arm mixed methods study |
| url | http://www.researchprotocols.org/2021/1/e17436/ |
| work_keys_str_mv | AT whitejudith effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT knightlaura effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT dacruzlyndon effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT stangapauloe effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT patrickhannah effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT powellhelen effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT berrylee effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT witherskathleen effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT carolanreesgrace effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy AT jacksontimothyl effectsoftheargusiiretinalprosthesissystemonthequalityoflifeofpatientswithultralowvisionduetoretinitispigmentosaprotocolforasinglearmmixedmethodsstudy |